{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T13:39:45Z","timestamp":1772026785775,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T00:00:00Z","timestamp":1576454400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Key Scientific Research Projects of Advanced Education Institutions of Department of Education of Henan Province","award":["19A320006"],"award-info":[{"award-number":["19A320006"]}]},{"name":"Health and Family Planning Technology Overseas Training Project of Henan Province","award":["2018028"],"award-info":[{"award-number":["2018028"]}]},{"name":"Youth Innovation Fund Project of the First Affiliated Hospital of Zhengzhou University","award":["201418"],"award-info":[{"award-number":["201418"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Downregulation of microRNA-338-3p (miR-338-3p) was detected in many malignant tumors, which indicated miR-338-3p might serve as a role of antioncogene in those cancers. The present study aimed to explore the roles of miR-338-3p in the growth and metastasis of ovarian cancer cells and elaborate the underlying possible molecular mechanism.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Multiply biomedical databases query and KEGG pathway enrichment assay were used to infilter possible target genes and downstream pathways regulated by miR-338-3p. Overexpression miR-338-3p lentiviral vectors were transfected into ovarian cancer OVCAR-3 and OVCAR-8 cells, cell proliferation, migration and invasion were analyzed by MTT, colony formation, transwell, Matrigel assay and xenograft mouse model. One 3\u2032-untranslated regions (UTRs) binding target gene of miR-338-3p, MACC1 (MET transcriptional regulator MACC1), and its regulated gene MET and downstream signaling pathway activities were examined by western blot.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Biomedical databases query indicated that miR-338-3p could target MACC1 gene and regulate Met, downstream Wnt\/Catenin beta and MEK\/ERK pathways. Rescue of miR-338-3p could inhibit the proliferation, migration and invasion of ovarian cancer cells, and suppress the growth and metastasis of xenograft tumor. Restoration of miR-338-3p could attenuate MACC1 and Met overexpression induced growth, epithelial to mesenchymal transition (EMT) and activities of Wnt\/Catenin beta and MEK\/ERK signaling in vitro and in vivo.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present data indicated that restoration of miR-338-3p could suppress the growth and metastasis of ovarian cancer cells, which might due to the inhibition of proliferation and EMT induced by MACC1, Met and its downstream Wnt\/Catenin beta and MEK\/ERK signaling pathways.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-019-1494-3","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T20:03:48Z","timestamp":1576526628000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["RETRACTED ARTICLE: MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt\/catenin beta and MEK\/ERK signaling pathways"],"prefix":"10.1186","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5610-9433","authenticated-orcid":false,"given":"Ruitao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huirong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gailing","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pengcheng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,12,16]]},"reference":[{"issue":"5","key":"1494_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646\u201374.","journal-title":"Cell"},{"issue":"6","key":"1494_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1158\/1078-0432.CCR-10-2307","volume":"17","author":"GE Konecny","year":"2011","unstructured":"Konecny GE, Winterhoff B, Kolarova T, Qi J, Manivong K, Dering J, et al. Expression of p16 and retinoblastoma determines response to CDK4\/6 inhibition in ovarian cancer. Clin Cancer Res. 2011;17(6):1591\u2013602.","journal-title":"Clin Cancer Res"},{"issue":"34","key":"1494_CR3","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, et al. Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients with platinum-resistant ovarian Cancer. J Clin Oncol. 2015;33(34):4015\u201322.","journal-title":"J Clin Oncol"},{"issue":"10106","key":"1494_CR4","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/S0140-6736(17)32418-2","volume":"390","author":"DS Dizon","year":"2017","unstructured":"Dizon DS. PARP inhibitors for targeted treatment in ovarian cancer. Lancet. 2017;390(10106):1929\u201330.","journal-title":"Lancet"},{"issue":"1","key":"1494_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"1494_CR6","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.4161\/cc.4.9.2032","volume":"4","author":"JT Mendell","year":"2005","unstructured":"Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle. 2005;4(9):1179\u201384.","journal-title":"Cell Cycle"},{"issue":"18","key":"1494_CR7","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1158\/1078-0432.CCR-12-0016","volume":"18","author":"J Gaedcke","year":"2012","unstructured":"Gaedcke J, Grade M, Camps J, Sokilde R, Kaczkowski B, Schetter AJ, et al. The rectal Cancer microRNAome - microRNA expression in rectal Cancer and matched Normal mucosa. Clin Cancer Res. 2012;18(18):4919\u201330.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1494_CR8","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1158\/1541-7786.MCR-13-0507","volume":"12","author":"B Guo","year":"2014","unstructured":"Guo B, Liu LY, Yao JY, Ma RL, Chang DM, Li ZF, et al. miR-338-3p suppresses gastric Cancer progression through a PTEN-AKT Axis by targeting P-REX2a. Mol Cancer Res. 2014;12(3):313\u201321.","journal-title":"Mol Cancer Res"},{"issue":"1","key":"1494_CR9","first-page":"33","volume":"20","author":"J Liu","year":"2019","unstructured":"Liu J, Cao LG, Zhao N, Feng Y, Yu Z, Li YH, et al. miR-338-3p inhibits A549 lung cancer cell proliferation and invasion by targeting AKT and beta-catenin signaling pathways. Mol Med Rep. 2019;20(1):33\u201340.","journal-title":"Mol Med Rep"},{"issue":"22","key":"1494_CR10","doi-asserted-by":"publisher","first-page":"3729","DOI":"10.1016\/j.febslet.2013.09.044","volume":"587","author":"X Chen","year":"2013","unstructured":"Chen X, Pan M, Han LL, Lu HT, Hao XW, Dong Q. miR-338-3p suppresses neuroblastoma proliferation, invasion and migration through targeting PREX2a. FEBS Lett. 2013;587(22):3729\u201337.","journal-title":"FEBS Lett"},{"key":"1494_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.biopha.2016.09.056","volume":"84","author":"T Zhang","year":"2016","unstructured":"Zhang T, Liu W, Zeng XC, Jiang N, Fu BS, Guo Y, et al. Down-regulation of microRNA-338-3p promoted angiogenesis in hepatocellular carcinoma. Biomed Pharmacother. 2016;84:583\u201391.","journal-title":"Biomed Pharmacother"},{"issue":"7","key":"1494_CR12","first-page":"3266","volume":"8","author":"Y Zhang","year":"2016","unstructured":"Zhang Y, Shi B, Chen J, Hu L, Zhao C. MiR-338-3p targets pyruvate kinase M2 and affects cell proliferation and metabolism of ovarian cancer. Am J Transl Res. 2016;8(7):3266\u201373.","journal-title":"Am J Transl Res"},{"issue":"5","key":"1494_CR13","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.3892\/ijo.2015.2929","volume":"46","author":"C Wen","year":"2015","unstructured":"Wen C, Liu X, Ma H, Zhang W, Li H. MiR3383p suppresses tumor growth of ovarian epithelial carcinoma by targeting Runx2. Int J Oncol. 2015;46(5):2277\u201385.","journal-title":"Int J Oncol"},{"issue":"6","key":"1494_CR14","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.7150\/jca.29502","volume":"10","author":"R Zhang","year":"2019","unstructured":"Zhang R, Shi H, Ren F, Liu Z, Ji P, Zhang W, et al. Down-regulation of miR-338-3p and up-regulation of MACC1 indicated poor prognosis of epithelial ovarian Cancer patients. J Cancer. 2019;10(6):1385\u201392.","journal-title":"J Cancer"},{"issue":"D1","key":"1494_CR15","doi-asserted-by":"publisher","first-page":"D812","DOI":"10.1093\/nar\/gkw1079","volume":"45","author":"Z Yang","year":"2017","unstructured":"Yang Z, Wu L, Wang A, Tang W, Zhao Y, Zhao H, et al. dbDEMC 2.0: updated database of differentially expressed miRNAs in human cancers. Nucleic Acids Res. 2017;45(D1):D812\u2013D8.","journal-title":"Nucleic Acids Res"},{"issue":"269","key":"1494_CR16","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J. Gao","year":"2013","unstructured":"Gao JJ, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal. Sci Signal. 2013;6(269):pl1.","journal-title":"Science Signaling"},{"issue":"4","key":"1494_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/bioinformatics\/btx627","volume":"34","author":"NW Wong","year":"2018","unstructured":"Wong NW, Chen YH, Chen S, Wang XW. OncomiR: an online resource for exploring pan-cancer microRNA dysregulation. Bioinform. 2018;34(4):713\u20135.","journal-title":"Bioinform"},{"issue":"4","key":"1494_CR18","doi-asserted-by":"publisher","first-page":"564","DOI":"10.3390\/ijms17040564","volume":"17","author":"Maarten Hamberg","year":"2016","unstructured":"Hamberg M, Backes C, Fehlmann T, Hart M, Meder B, Meese E, et al. miRTargetLink-miRNAs, Genes and Interaction Networks. Int J Mol Sci. 2016;17(4):564.","journal-title":"International Journal of Molecular Sciences"},{"issue":"1","key":"1494_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cell.2004.12.035","volume":"120","author":"BP Lewis","year":"2005","unstructured":"Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15\u201320.","journal-title":"Cell"},{"issue":"W1","key":"1494_CR20","doi-asserted-by":"publisher","first-page":"W169","DOI":"10.1093\/nar\/gkt393","volume":"41","author":"MD Paraskevopoulou","year":"2013","unstructured":"Paraskevopoulou MD, Georgakilas G, Kostoulas N, Vlachos IS, Vergoulis T, Reczko M, et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013;41(W1):W169\u2013W73.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"1494_CR21","doi-asserted-by":"publisher","first-page":"D90","DOI":"10.1093\/nar\/gkw926","volume":"45","author":"C Backes","year":"2017","unstructured":"Backes C, Kehl T, Stockel D, Fehlmann T, Schneider L, Meese E, et al. miRPathDB: a new dictionary on microRNAs and target pathways. Nucleic Acids Res. 2017;45(D1):D90\u2013D6.","journal-title":"Nucleic Acids Res"},{"issue":"D1","key":"1494_CR22","doi-asserted-by":"publisher","first-page":"D296","DOI":"10.1093\/nar\/gkx1067","volume":"46","author":"CH Chou","year":"2018","unstructured":"Chou CH, Shrestha S, Yang CD, Chang NW, Lin YL, Liao KW, et al. miRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 2018;46(D1):D296\u2013302.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"1494_CR23","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.3892\/or.2015.3723","volume":"33","author":"RT Zhang","year":"2015","unstructured":"Zhang RT, Shi HR, Ren F, Liu HN, Zhang MH, Deng YX, et al. Misregulation of polo-like protein kinase 1, P53 and P21(WAF1) in epithelial ovarian cancer suggests poor prognosis. Oncol Rep. 2015;33(3):1235\u201342.","journal-title":"Oncol Rep"},{"issue":"15_suppl","key":"1494_CR24","doi-asserted-by":"publisher","first-page":"e22010","DOI":"10.1200\/jco.2014.32.15_suppl.e22010","volume":"32","author":"Na Huang","year":"2014","unstructured":"Huang N, Wu ZZ, Zhou MY, Wang L, Ma HR, Shi M, et al. Effect of MiR-338-3p on epithelial-mesenchymal transition in gastric cancer cells by targeting ZEB2 and MACC1 and regulation of MACC1\/c-Met signaling. J Clin Oncol. 2014;32(15_suppl):e22010\u2013e22010.","journal-title":"Journal of Clinical Oncology"},{"key":"1494_CR25","doi-asserted-by":"crossref","unstructured":"Shang C, Hong Y, Guo Y, Xue YX. Mir-338-3p inhibits malignant biological behaviors of Glioma cells by targeting MACC1 gene. Med Sci Monitor. 2016;22:710\u20136.","DOI":"10.12659\/MSM.897055"},{"issue":"4","key":"1494_CR26","first-page":"2256","volume":"11","author":"T Zou","year":"2018","unstructured":"Zou T, Duan J, Liang JT, Shi HJ, Zhen TT, Li H, et al. miR-338-3p suppresses colorectal cancer proliferation and progression by inhibiting MACC1. Int J Clin Exp Patho. 2018;11(4):2256\u201367.","journal-title":"Int J Clin Exp Patho"},{"issue":"4","key":"1494_CR27","first-page":"2807","volume":"17","author":"ML Lu","year":"2019","unstructured":"Lu ML, Huang H, Yang JH, Li J, Zhao GF, Li WH, et al. miR-338-3p regulates the proliferation, apoptosis and migration of SW480 cells by targeting MACC1. Exp Ther Med. 2019;17(4):2807\u201314.","journal-title":"Exp Ther Med"},{"issue":"2","key":"1494_CR28","first-page":"997","volume":"18","author":"CH Zhang","year":"2019","unstructured":"Zhang CH, Li H, Wang JL, Zhang JB, Hou XQ. MicroRNA-338-3p suppresses cell proliferation, migration and invasion in human malignant melanoma by targeting MACC1. Exp Ther Med. 2019;18(2):997\u20131004.","journal-title":"Exp Ther Med"},{"issue":"23","key":"1494_CR29","first-page":"5342","volume":"21","author":"FF Hua","year":"2017","unstructured":"Hua FF, Liu SS, Zhu LH, Wang YH, Liang X, Ma N, et al. MiRNA-338-3p regulates cervical cancer cells proliferation by targeting MACC1 through MAPK signaling pathway. Eur Rev Med Pharmaco. 2017;21(23):5342\u201352.","journal-title":"Eur Rev Med Pharmaco"},{"issue":"5","key":"1494_CR30","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1080\/14737140.2017.1299575","volume":"17","author":"P Jessmon","year":"2017","unstructured":"Jessmon P, Boulanger T, Zhou W, Patwardhan P. Epidemiology and treatment patterns of epithelial ovarian cancer. Expert Rev Anticanc. 2017;17(5):427\u201337.","journal-title":"Expert Rev Anticanc"},{"key":"1494_CR31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1093\/annonc\/mdx443","volume":"28","author":"EA Eisenhauer","year":"2017","unstructured":"Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28:61\u20135.","journal-title":"Ann Oncol"},{"issue":"7644","key":"1494_CR32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/543183a","volume":"543","author":"K Adelman","year":"2017","unstructured":"Adelman K, Egan E. NON-CODING RNA more uses for genomic junk. Nat. 2017;543(7644):183\u20135.","journal-title":"Nat"},{"issue":"1","key":"1494_CR33","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/nrc.2017.99","volume":"18","author":"E Anastasiadou","year":"2018","unstructured":"Anastasiadou E, Jacob LS, Slack FJ. Non-coding RNA networks in cancer. Nat Rev Cancer. 2018;18(1):5\u201318.","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1494_CR34","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/nrg2504","volume":"10","author":"M Ghildiyal","year":"2009","unstructured":"Ghildiyal M, Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009;10(2):94\u2013108.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"1494_CR35","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1093\/carcin\/bgs140","volume":"33","author":"MV Iorio","year":"2012","unstructured":"Iorio MV, Croce CM. microRNA involvement in human cancer. Carcinog. 2012;33(6):1126\u201333.","journal-title":"Carcinog"},{"issue":"24","key":"1494_CR36","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.1042\/BCJ20170079","volume":"474","author":"O Slaby","year":"2017","unstructured":"Slaby O, Laga R, Sedlacek O. Therapeutic targeting of non-coding RNAs in cancer. Biochem J. 2017;474(24):4219\u201351.","journal-title":"Biochem J"},{"issue":"11","key":"1494_CR37","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3390\/cells7110203","volume":"7","author":"Adele Vivacqua","year":"2018","unstructured":"Vivacqua A, Sebastiani A, Miglietta AM, Rigiracciolo DC, Cirillo F, Galli GR, et al. MiR-338-3p Is Regulated by Estrogens through GPER in Breast Cancer Cells and Cancer-Associated Fibroblasts CAFs. Cells. 2018;7(11).","journal-title":"Cells"},{"issue":"1","key":"1494_CR38","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3233\/CBM-170339","volume":"21","author":"S Liu","year":"2017","unstructured":"Liu S, Suo J, Wang C, Sun X, Wang D, He L, et al. Downregulation of tissue miR-338-3p predicts unfavorable prognosis of gastric cancer. Cancer Biomark. 2017;21(1):117\u201322.","journal-title":"Cancer Biomark"},{"issue":"3","key":"1494_CR39","doi-asserted-by":"publisher","first-page":"3951","DOI":"10.3892\/mmr.2015.3820","volume":"12","author":"X Li","year":"2015","unstructured":"Li X, Li Z, Yang G, Pan Z. MicroRNA-338-3p suppresses tumor growth of esophageal squamous cell carcinoma in vitro and in vivo. Mol Med Rep. 2015;12(3):3951\u20137.","journal-title":"Mol Med Rep"},{"issue":"5740","key":"1494_CR40","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1126\/science.1111444","volume":"309","author":"PD Zamore","year":"2005","unstructured":"Zamore PD, Haley B. Ribo-gnome: the big world of small RNAs. Sci. 2005;309(5740):1519\u201324.","journal-title":"Sci"},{"issue":"1","key":"1494_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1756-9966-30-83","volume":"30","author":"Ruitao Zhang","year":"2011","unstructured":"Zhang RT, Shi HR, Chen ZM, Wu QH, Ren F, Huang HL. Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells. J Exp Clin Canc Res. 2011;30:83.","journal-title":"Journal of Experimental & Clinical Cancer Research"},{"issue":"7","key":"1494_CR42","first-page":"2689","volume":"30","author":"A Shirahata","year":"2010","unstructured":"Shirahata A, Shinmura K, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, et al. MACC1 as a marker for advanced colorectal carcinoma. Anticancer Res. 2010;30(7):2689\u201392.","journal-title":"Anticancer Res"},{"issue":"9","key":"1494_CR43","first-page":"3441","volume":"30","author":"A Shirahata","year":"2010","unstructured":"Shirahata A, Sakata M, Kitamura Y, Sakuraba K, Yokomizo K, Goto T, et al. MACC 1 as a marker for peritoneal-disseminated gastric carcinoma. Anticancer Res. 2010;30(9):3441\u20134.","journal-title":"Anticancer Res"},{"issue":"3","key":"1494_CR44","first-page":"777","volume":"31","author":"A Shirahata","year":"2011","unstructured":"Shirahata A, Fan W, Sakuraba K, Yokomizo K, Goto T, Mizukami H, et al. MACC 1 as a marker for vascular invasive hepatocellular carcinoma. Anticancer Res. 2011;31(3):777\u201380.","journal-title":"Anticancer Res"},{"issue":"4","key":"1494_CR45","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.jtcvs.2010.09.044","volume":"141","author":"H Shimokawa","year":"2011","unstructured":"Shimokawa H, Uramoto H, Onitsuka T, Gu CD, Hanagiri T, Oyama T, et al. Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiov Sur. 2011;141(4):895\u20138.","journal-title":"J Thorac Cardiov Sur"},{"issue":"15","key":"1494_CR46","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.4161\/cc.8.15.9018","volume":"8","author":"U Stein","year":"2009","unstructured":"Stein U, Smith J, Walther W, Arlt F. MACC1 controls met what a difference an Sp1 site makes. Cell Cycle. 2009;8(15):2467\u20139.","journal-title":"Cell Cycle"},{"issue":"2","key":"1494_CR47","doi-asserted-by":"publisher","first-page":"317","DOI":"10.18388\/abp.2009_2464","volume":"56","author":"K Kokoszynska","year":"2009","unstructured":"Kokoszynska K, Krynski J, Rychlewski L, Wyrwicz LAS. Unexpected domain composition of MACC1 links MET signaling and apoptosis. Acta Biochim Pol. 2009;56(2):317\u201323.","journal-title":"Acta Biochim Pol"},{"issue":"5143","key":"1494_CR48","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.7505952","volume":"263","author":"I Tsarfaty","year":"1994","unstructured":"Tsarfaty I, Rong S, Resau JH, Rulong S, da Silva PP, Vande Woude GF. The met proto-oncogene mesenchymal to epithelial cell conversion. Science. 1994;263(5143):98\u2013101.","journal-title":"Science."},{"issue":"6","key":"1494_CR49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2174\/156652408785747933","volume":"8","author":"HY Zhou","year":"2008","unstructured":"Zhou HY, Pon YL, Wong AS. HGF\/MET signaling in ovarian cancer. Curr Mol Med. 2008;8(6):469\u201380.","journal-title":"Curr Mol Med"},{"issue":"13","key":"1494_CR50","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.2174\/138945012803530044","volume":"13","author":"RY Huang","year":"2012","unstructured":"Huang RY, Chung VY, Thiery JP. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer. Curr Drug Targets. 2012;13(13):1649\u201353.","journal-title":"Curr Drug Targets"},{"issue":"6","key":"1494_CR51","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/j.ceb.2003.10.006","volume":"15","author":"JP Thiery","year":"2003","unstructured":"Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol. 2003;15(6):740\u20136.","journal-title":"Curr Opin Cell Biol"},{"issue":"1","key":"1494_CR52","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S1383-5742(03)00033-4","volume":"566","author":"J Gotzmann","year":"2004","unstructured":"Gotzmann J, Mikula M, Eger A, Schulte-Hermann R, Foisner R, Beug H, et al. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res. 2004;566(1):9\u201320.","journal-title":"Mutat Res"},{"issue":"8","key":"1494_CR53","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1091\/mbc.9.8.2185","volume":"9","author":"S Potempa","year":"1998","unstructured":"Potempa S, Ridley AJ. Activation of both MAP kinase and phosphatidylinositide 3-kinase by Ras is required for hepatocyte growth factor scatter factor-induced adherens junction disassembly. Mol Biol Cell. 1998;9(8):2185\u2013200.","journal-title":"Mol Biol Cell"},{"key":"1494_CR54","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1146\/annurev.cellbio.20.010403.113126","volume":"20","author":"CY Logan","year":"2004","unstructured":"Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781\u2013810.","journal-title":"Annu Rev Cell Dev Biol"},{"issue":"6803","key":"1494_CR55","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/35035117","volume":"407","author":"K Tamai","year":"2000","unstructured":"Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama Y, et al. LDL-receptor-related proteins in Wnt signal transduction. Nat. 2000;407(6803):530\u20135.","journal-title":"Nat"}],"updated-by":[{"DOI":"10.1186\/s13046-024-02978-0","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000},"record-id":"51905"},{"DOI":"10.1186\/s13046-024-02978-0","type":"retraction","label":"Retraction","source":"publisher","updated":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T00:00:00Z","timestamp":1707955200000}}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-019-1494-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-019-1494-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T08:08:53Z","timestamp":1708330133000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-019-1494-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,16]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["1494"],"URL":"https:\/\/doi.org\/10.1186\/s13046-019-1494-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,16]]},"assertion":[{"value":"19 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article has been retracted. Please see the Retraction Notice for more detail:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13046-024-02978-0","URL":"https:\/\/doi.org\/10.1186\/s13046-024-02978-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Animal experiment protocols performed in present study were approved by the ethics committee of the first affiliated hospital of Zhengzhou University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declare that they have no competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"494"}}